As the COVID-19 respiratory virus spreads around the world, please know that the IMF is here for you.
People living with myeloma are at an increased risk. “Myeloma patients have compromised immune systems and are highly vulnerable to new infections,” says IMF Chairman Dr. Brian G.M. Durie.
“It is important to be proactive and guard against infection from unknown sources.”
On this page, you will find updated guidance to keep you safe. Featured are Dr. Durie’s blogs and FAQs, aimed specifically at multiple myeloma patients, and links to the best sources of COVID-19 news.
Practices to minimize your risk include:
- Masks are an essential protective measure for myeloma patients.
- If the community level of COVID-19 delta variant is high (above 8%), avoid contact with individuals not wearing a mask.
- Avoiding close contact with people who are sick. Practice social distancing by staying 6 feet away from others. Isolation at home is best.
- Avoiding touching your eyes, nose, and mouth.
- Clean and disinfect frequently touched objects and surfaces using a regular household cleaning spray or wipe.
- Wash your hands often with soap and water for at least 20 seconds, especially after going to the bathroom; before eating; and after blowing your nose, coughing, or sneezing. If soap and water are not readily available, use an alcohol-based hand sanitizer with at least 60% alcohol.
Please be safe and well, and please contact the IMF InfoLine with any questions.
Read this page for the IMF’s latest recommendations on receiving the COVID-19 vaccine if you have multiple myeloma (MM), smoldering multiple myeloma (SMM), or monoclonal gammopathy of undetermined significance (MGUS).
The groundbreaking gene editing technology known as CRISPR could pave the way to the elimination of COVID-19 virus production in the future, says IMF Chairman Dr. Brian G.M. Durie. And is a new “variant of concern” on the horizon?
published September 2, 2021
Late Thursday, August 12, the FDA authorized extra vaccine doses for immunocompromised patients to bolster protection against COVID-19.
published August 12, 2021
IMF Chairman Dr. Brian G.M. Durie offers guidance to myeloma patients on how to navigate the latest wave of COVID-19 infections and examines the state of booster shots.
published August 5, 2021
Despite receiving vaccinations, immunocompromised individuals can develop very low levels of antibodies. France and Israel have approved a booster vaccination for the vulnerable. IMF Chairman Dr. Brian G.M. Durie says it’s time for the U.S. to do the same.
published July 15, 2021
#ASKDRDURIE COVID-19 FAQs
As the COVID-19 respiratory virus spreads across the country and around the world, myeloma patient safety is a paramount concern of patients, families and caregivers.
Watch Dr. Durie's COVID-19 FAQ video series to learn more how COVID-19 has affected the myeloma community.
Videos in the COVID-19 FAQ Series
- How can myeloma pts reduce the possibility of being exposed to the coronavirus?
- What do myeloma patients need to know about COVID-19?
- Do myeloma patients need to adjust their treatment?
- What are some of the treatment modifications myeloma patients should consider?
- What are the risk factors that could lead myeloma patients to develop serious consequences from the COVID-19 infection?
- What precautions should myeloma patients take when getting their groceries?
- Is it safe for myeloma patients to take walks?
- Is physical distancing still recommended for myeloma patients?
- Can myeloma patients avoid contracting the COVID-19 infection?
- Should Myeloma patients undergo routine COVID-19 antibody testing?
- Are MGUS and smoldering multiple myeloma (SMM) patients considered to be at higher risk for severe consequences from a COVID-19 infection?
- If a myeloma patient takes Revlimid® (lenalidomide) as maintenance treatment, should this patient continue with that treatment during the pandemic?
- Is it safe for myeloma patients to resume in-person doctors' visits?
- Should myeloma patients undergo ASCT during the pandemic?
- Is dexamethasone helpful against the COVID-19 infection?
- Is it safe for myeloma patients to travel by airplane?
- How high of a risk do asymptomatic carriers pose to myeloma patients?
- Is Ninlaro® a safe treatment alternative for myeloma patients during the pandemic?
- Should myeloma patients visit the dentist during the pandemic?
- What is a bubble? And should myeloma patients exercise this practice?
- How should myeloma patients conduct their follow-up appointments?
- Have the safety recommendations changed for myeloma patients?
- With the COVID-19 pandemic still a concern, what does the future hold for myeloma patients?
- For myeloma patients, how important is it to wear a mask?
- How can the “Swiss cheese” model help myeloma patients stay safe?
- Should myeloma patients get vaccinated against COVID-19?
- What should myeloma patients know about the COVID-19 variants?
- How can myeloma patients de-stress during the ongoing pandemic?
- Can COVID-19 vaccinations trigger active myeloma?
- Should myeloma patients check their COVID-19 antibody levels post vaccination?
- When can myeloma patients restart therapy after recovering from COVID-19?
- How common are COVID-19 infections in myeloma patients?
- Which COVID-19 vaccine should myeloma patients get?
- How can myeloma patients protect themselves against the Delta variant?
- What should myeloma patients know about antibody testing and booster shots?
- Should myeloma patients get a COVID-19 booster shot?
- Should myeloma patients continue to wear a mask?
- Should myeloma patients undergo an autologous stem cell transplant during the Delta variant surge?
We wanted to take some time and keep you up to date on the Federal Government’s response regarding COVID-19. We have received a lot of questions from patients and their families about what is included in the government has done to address the virus.
COVID-19 External Resources:
- World Health Organization
- Centers for Disease Control
- FDA Grants Emergency Use Authorization for COVID-19 Drug
- Cancer Emergency Fund
- FDA: A Message to Patients With Cancer and Health Care Providers About COVID-19
- FDA Issues Guidance for Conducting Clinical Trials
- US Government Response
- Global Dashboard of confirmed cases
- Medicare and Medicaid
- Watch Out for Medicare Fraud (Possible COVID-19 scams)
- VA and Coronavirus
- The American Red Cross: Steps to Help Cope with the Evolving Coronavirus Situation
- Considerations of COVID-19–Specific Myeloma Guidelines in New York City
- Multiple Myeloma Medicare Access
- PSA Safe Grocery Shopping in COVID-19 Pandemic
- How I Am Managing My Patients With Myeloma During the COVID-19 Pandemic
- LLS COVID-19 Patient Financial Aid Program - currently closed
- Healthwell Foundation COVID-19 Ancillary Costs Support - currently closed
Pharma Resources:
- Learn how the BMS Foundation is extending additional support "to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic through the first six months of 2021."
- COVID-19 Emergency Food Assistance Program by Team Rubicon and Bristol Myers Squibb
- GSK COVID-19 statement of support Patient Groups
- GSK Compassionate Use (Expanded Access) statement for Patient Groups
- Takeda Oncology Expands Patient Assistance in the U.S. During COVID-19 Crisis
- Takeda Oncology 1 Point portal
- Bristol Myers Squibb COVID-19 patient support
- Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
- Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
- Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologist, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape. Additionally, Dr. Brian G.M. Durie reviews and approves all medical content on this website.
Last Medical Review: January 12, 2021